BRIEF published on 05/01/2024 at 08:05, 6 months 20 days ago PREDILIFE Receives Updated Stock Analysis from In Extenso Finance AI Healthcare In Extenso Finance Stock Analysis PREDILIFE MammoRisk
PRESS RELEASE published on 05/01/2024 at 08:00, 6 months 20 days ago IN EXTENSO FINANCE UPDATES COVERAGE ON PREDILIFE STOCK; TARGET PRICE OF EUR 25.07 REPRESENTS +391% POTENTIAL UPSIDE In Extenso Finance updates coverage on Predilife stock, raising target price to €25.07 (+391% potential upside). Predilife pioneers in AI for personalized medicine Target Price In Extenso Finance Personalized Medicine Predilife Stock AI Methods
BRIEF published on 04/30/2024 at 18:05, 6 months 20 days ago Results of the Ordinary and Extraordinary General Meeting of Predilife Annual Accounts General Assembly Company Shares PREDILIFE Company Administration
BRIEF published on 04/25/2024 at 18:10, 6 months 25 days ago Valorization of the MammoRisk® software by PREDILIFE Artificial Intelligence PREDILIFE MammoRisk Software Evaluation Breast Cancer
BRIEF published on 04/25/2024 at 18:05, 6 months 25 days ago Valuation of MammoRisk® Software Announced by PREDILIFE PREDILIFE Breast Cancer MammoRisk Valuation Stratified Screening Predictive Medicine
PRESS RELEASE published on 04/25/2024 at 18:00, 6 months 25 days ago Valuation of MammoRisk(R) software PREDILIFE announces valuation of MammoRisk® software by SORGEM Evaluation, determining a value between €191.7 million and €223.3 million. MammoRisk® is a pioneering solution in breast cancer screening targeted at women aged 40 and over Valuation PREDILIFE MammoRisk® Software SORGEM Evaluation Breast Cancer Screening
BRIEF published on 04/24/2024 at 18:35, 6 months 26 days ago PROVISION OF PREDILIFE’S 2023 ANNUAL FINANCIAL REPORT Artificial Intelligence Financial Report 2023 Euronext Growth PREDILIFE
Published on 11/21/2024 at 13:30, 30 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 30 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 1 hour ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 1 hour ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 1 hour ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 25 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 45 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 2 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 40 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 15 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 15 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
